RE:RE:RE:RE:Inflation Reduction Act (IRA) boosts biological drugs March 04, 2024 - IRA Drives Pfizer’s Decision to Focus on Biologics, Not Small Molecules. By 2030, Pfizer expects biologics such as antibody-drug conjugates (ADCs) and bispecific antibodies to contribute approximately 65% of its oncology revenues—up from 6% in 2023, a more than 10-fold increase. At the same time, company leaders said that the mix of small molecule drugs in its cancer portfolio will plummet from 94% last year to 35% in 2030.
“Biologics represent a more durable revenue potential based on a number of factors, including differentiated access and affordability to the patient, IRA considerations and patent expiration timeline,” Suneet Varma, commercial president of Pfizer Oncology, told investors at Thursday’s event.
https://www.biospace.com/article/ira-drives-pfizer-s-decision-to-focus-on-biologics-not-small-molecules/
Upon Pelareorep's Accelerated Approval for HER2- negative Breast Cancer in 2024, market exclusivity would extend until 2037. And with market research projections indicating that the overall breast cancer market will be valued at US$73.68 billion by 2032, with a compound annual growth rate (CAGR) of 9.9%, the market is projected to grow to approximately US$118.56 billion by 2037.
https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-ord-shs?postid=35919246